NURS 751 Week 1 Neuro Workshop Paper on Anti-NMDA Receptor Encephalitis Example

When the Antibody Is the Illness: The Neurobiology of Anti-NMDA Receptor Encephalitis and Why It Is Mistaken for Primary Psychosis

Introduction

A roommate drives a 23-year-old graduate student to the emergency department after four days of almost no sleep, rapid speech and a conviction that her professors are recording her through her laptop. She had a headache and low fever the week before. She has no psychiatric history and no substance use. She is admitted to the psychiatric unit with a working diagnosis of brief psychotic disorder and started on an antipsychotic. Over the next week she becomes rigid and mute, her heart rate swings between 50 and 140, and on day eleven she has a generalized seizure and begins making repetitive chewing movements. Cerebrospinal fluid testing finds antibodies to the NMDA receptor, and a pelvic ultrasound shows an ovarian teratoma.

This composite case follows a pattern described in reports of anti-N-methyl-D-aspartate receptor encephalitis, in which a 33-year-old woman with ten days of acute behavioral and psychiatric symptoms was first managed as a primary psychiatric patient until fluctuating consciousness and involuntary movements pointed to a neurological cause (Ghimire et al., 2026). Anti-NMDA receptor encephalitis is an autoimmune disorder in which antibodies against a glutamate receptor cause a recognizable progression from psychiatric symptoms to severe neurological illness. This paper explains the neurobiology of the disorder, from the receptor itself to the immune response that targets it, and shows how that neurobiology produces each stage of the illness. It then reviews diagnosis, treatment and outcomes and closes with implications for psychiatric nurse practitioners, who are often the first clinicians to see these patients.

The NMDA Receptor

The NMDA receptor is one of the brain's main ionotropic glutamate receptors. Each receptor is a complex of four subunits, two GluN1 subunits, sometimes called NR1, and two others, usually GluN2. When glutamate binds and the cell membrane is already depolarized, a magnesium ion that blocks the channel at rest is expelled, and calcium flows into the neuron. This dual requirement, chemical and electrical, makes the receptor a coincidence detector: it opens only when a presynaptic signal arrives at a neuron that is already active. The calcium entry that follows triggers the intracellular changes underlying long-term potentiation, the strengthening of synapses that supports learning and memory.

NMDA receptors are dense in the hippocampus, the prefrontal cortex and the limbic system, and they are present on both excitatory pyramidal neurons and inhibitory GABAergic interneurons. Their function in these circuits links them to memory, attention, emotion and the integration of perception. Pharmacology has long suggested what happens when they fail. Phencyclidine and ketamine, which block the NMDA receptor channel, produce in healthy people a state resembling schizophrenia, with paranoia, disorganized thinking, perceptual distortion and negative symptoms. That observation is the basis of the NMDA receptor hypofunction model of schizophrenia, and anti-NMDA receptor encephalitis has become a natural experiment that supports it.

How Antibodies Disrupt the Receptor

In anti-NMDA receptor encephalitis, the patient produces immunoglobulin G antibodies against the GluN1 subunit. Their role is not merely associated with the disease; it is causal. Experiments in which human antibodies, monoclonal or polyclonal, were transferred to animals, and experiments with active immunization, have demonstrated that the antibodies are pathogenic, mainly through their action on GluN1 (Dame et al., 2026). The antibodies bind the receptor and cross-link neighboring receptors, which are then internalized by the neuron. The result is a reduction in the number of receptors at the synapse rather than the death of neurons. Because the neurons survive, the deficit is in principle reversible once antibody levels fall, which is why patients who appear profoundly ill can recover.

The source of the antibodies has been traced in detail. Autoreactive B cells are found in the blood, in the cerebrospinal fluid, in ovarian teratomas and in cervical lymph nodes; they include memory B cells and antibody-secreting cells, often clonally expanded and antigen-experienced (Dame et al., 2026). Antibody production within the central nervous system, behind the blood-brain barrier, helps explain why antibodies in cerebrospinal fluid are more reliable for diagnosis than those in serum, and why treatment must reach B cells and plasma cells rather than only remove antibodies already circulating. The patient's neurons are intact; what has been taken away is the receptor, and what has been taken away can be given back.

From Mechanism to Symptoms

The illness typically unfolds in stages, and each stage can be understood through the loss of NMDA receptor function in different circuits. A prodrome of headache, fever or a viral-like illness often comes first. The psychiatric stage follows: anxiety, insomnia, agitation, paranoid or grandiose delusions, hallucinations, mania-like behavior, disorganized speech and sometimes catatonia. These symptoms correspond to the hypofunction model. When NMDA receptors on inhibitory interneurons in the cortex and limbic system are lost, those interneurons fire less, pyramidal neurons are released from inhibition and glutamate signaling becomes disordered, producing the perceptual and cognitive disruption seen in psychosis. Loss of receptors in the hippocampus contributes to memory impairment, which patients often cannot recall afterward.

As receptor loss deepens, patients move into a stage of decreased responsiveness, with mutism, staring and catatonic features, and then into a neurological stage. Seizures arise as the balance between excitation and inhibition fails. Orofacial dyskinesias, such as chewing and lip-smacking, and choreoathetoid movements of the limbs reflect disruption of basal ganglia circuits. Autonomic instability, including swings in heart rate, blood pressure and temperature, and central hypoventilation reflect involvement of brainstem and hypothalamic pathways. Some patients require intensive care for months. In an international cohort of 45 patients who remained in a vegetative state for nine months or longer, impaired consciousness began a median of nine days after symptom onset, and 13 patients were resuscitated from dysautonomic cardiac arrest (Guasp et al., 2026).

Triggers of the Immune Response

Two triggers are well established. Ovarian teratomas, which may contain neural tissue expressing NMDA receptors, are present in about 20% of patients, and the immune response against the receptor in the tumor appears to break tolerance to the same receptor in the brain (Dame et al., 2026). The second trigger is herpes simplex virus encephalitis, after which autoimmune NMDA receptor encephalitis develops in roughly a quarter to a third of patients (Dame et al., 2026). A systematic review of 556 published cases of autoimmune encephalitis linked to viral infection or vaccination found that herpes simplex infection with NMDA receptor encephalitis was the most frequent association, outnumbering all other virus and autoimmune encephalitis combinations together, and was almost entirely attributable to preceding herpes simplex encephalitis (Bamberg et al., 2026). Viral destruction of neurons may expose receptor antigens to the immune system. In many patients, no trigger is found.

Diagnosis and Differential Diagnosis

The diagnosis rests on clinical features and the detection of antibodies to the GluN1 subunit in cerebrospinal fluid. Supporting findings include lymphocytic pleocytosis in the cerebrospinal fluid, electroencephalographic slowing or epileptic activity, and in some patients a pattern called extreme delta brush. Brain magnetic resonance imaging is normal in many patients, which can falsely reassure. Every woman with the diagnosis should be screened for an ovarian teratoma with pelvic imaging.

For psychiatric clinicians, the challenge is recognizing the disorder in a patient who looks like a first episode of psychosis or mania. Red flags include a viral-like prodrome, rapid progression over days, new seizures, abnormal movements, fluctuating consciousness, autonomic instability, speech reduction or mutism, catatonia and poor tolerance of antipsychotics, including rigidity, fever or autonomic changes that resemble neuroleptic malignant syndrome. In the case reported by Ghimire et al. (2026), the appearance of fluctuating consciousness and involuntary movements during psychiatric treatment prompted the neurological workup that found antibodies and a teratoma. The differential diagnosis includes primary psychotic and bipolar disorders, substance-induced psychosis, neuroleptic malignant syndrome, infectious encephalitis, other autoimmune encephalitides and metabolic or toxic encephalopathies.

Treatment and Outcomes

Treatment has two aims: removing the source of antigen and suppressing the immune response. Teratomas are removed surgically. First-line immunotherapy consists of corticosteroids, intravenous immunoglobulin or plasma exchange, often in combination. When the response is inadequate, second-line therapy with rituximab, which depletes B cells, or cyclophosphamide follows. The immunopathology supports early treatment, since interrupting the response that generates pathogenic antibodies is the goal (Dame et al., 2026). Supportive care for agitation, seizures, autonomic instability and hypoventilation is often intensive.

Outcomes are better than earlier referral-center studies suggested. In a population-based cohort of 72 patients in Southern California followed for a median of 4.7 years, first-line immunotherapy began a median of 19 days after symptom onset, and 63.8% received second-line therapy. The proportion with a favorable functional outcome rose from 22% at discharge to 84.5% at the most recent follow-up, relapses occurred in only 4.1%, and mortality fell from 17.4% in 2009 to 2013 to 4.1% in 2014 to 2022, in parallel with faster escalation to rituximab (Hernandez-Lopez et al., 2026). Even the sickest patients can recover. In the cohort of patients in a prolonged vegetative state, after a median of five years, 33% had completely recovered and returned to their previous activities and another 29% had substantially improved, while 13% had died; five patients began following commands a median of eleven months after their last immunotherapy (Guasp et al., 2026). Recovery is slow, and residual cognitive and psychiatric symptoms may persist for months.

Implications for the Psychiatric Nurse Practitioner

Anti-NMDA receptor encephalitis is rare, but its first presentation is often to psychiatric services, and early recognition changes outcomes. The psychiatric mental health nurse practitioner can apply three lessons. First, a first episode of psychosis is a diagnosis that requires medical exclusion, especially in a young woman with a prodrome, rapid onset or neurological signs. Second, new rigidity, fever or autonomic instability after an antipsychotic is started should prompt consideration of both neuroleptic malignant syndrome and an underlying encephalitis, and a lumbar puncture should be advocated rather than deferred. Third, recovery from the acute illness often leaves psychiatric sequelae, including mood symptoms, impulsivity and cognitive deficits, that the nurse practitioner may manage for months, with attention to medication sensitivity. Families also need help understanding the illness. Many will have watched a daughter or partner become frightening and unrecognizable, and some will have been told at first that the cause was psychiatric. Explaining that the symptoms came from antibodies acting on a receptor, that the brain was not destroyed and that recovery is likely but slow gives them a framework for patience during months of rehabilitation. It also helps the patient, who may remember little of the acute illness and feel ashamed of what others describe, to understand that the behavior was a symptom of an immune disease.

Conclusion

Anti-NMDA receptor encephalitis shows how a psychiatric syndrome can arise from a specific and reversible disruption of brain chemistry. Antibodies to the GluN1 subunit remove NMDA receptors from the neuronal surface, and the resulting hypofunction produces psychosis, catatonia, seizures, dyskinesias and autonomic instability in a predictable sequence. Ovarian teratomas and herpes simplex encephalitis are the established triggers. With prompt immunotherapy and tumor removal, most patients recover well, and even patients who remain unresponsive for many months may improve. For the psychiatric nurse practitioner, the disorder is a reminder that every new psychosis deserves a neurological question.

References

Bamberg, S., Schulte-Frankenfeld, P. M., & Kreye, J. (2026). Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis. Brain, Behavior, & Immunity: Health, 56, Article 101301. https://doi.org/10.1016/j.bbih.2026.101301

Dame, T., Themas, K., Repousi, E., Constantinides, V. C., Koros, C., Papageorgiou, S. G., & Stathopoulos, P. (2026). Immunopathogenesis of NMDA receptor encephalitis. Clinical Immunology, 287, Article 110747. https://doi.org/10.1016/j.clim.2026.110747

Ghimire, B., Bhatt, J., Niraula, S., Shrestha, B., Lamsal, A. B., & Upadhyaya, S. (2026). Delayed recognition of anti-NMDAR encephalitis mimicking primary psychiatric illness: A case report. Clinical Case Reports, 14(9), Article e73426. https://doi.org/10.1002/ccr3.73426

Guasp, M., Simabukuro, M. M., Muñoz-Sánchez, G., Brenner, J., Wurdack, K., Wang, K., Lalive, P. H., Olivé-Cirera, G., Yeung, J., Wandinger, K. P., Macher, S., Di Liberto, G., Lancaster, E., Casadevall, T., Martínez-González, M. J., Fernández-Carrasco, J. P., Shibata, M., Fukao, E., Mishima, T., . . . Zieglgänsberger, D. (2026). Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: A retrospective international cohort study. The Lancet Neurology, 25(4), 368-378. https://doi.org/10.1016/S1474-4422(26)00030-X

Hernandez-Lopez, V., Smith, J. B., Alsalek, S., Scott, J. N., Schwarzmann, K. B., Budhathoki, S., & Langer-Gould, A. (2026). Anti-NMDA receptor encephalitis outcomes in a population-based cohort. Journal of Neurology, 273(8), Article 462. https://doi.org/10.1007/s00415-026-13990-z